Abstract
We describe the discovery of a novel indazole-based scaffold that represents the "first-in-class" dual Hsp90/tubulin binding compound. Individual known ligands for both targets shared similar 3',4',5'- trimethoxyphenyl cores, and from this it was hypothesized that application of an integrated ligand and structure-based virtual screening (VS) workflow could yield a single scaffold with dual binding affinity. Following validation of the VS protocol, we successfully identified a novel dual inhibitor, sourced from a commercial screening collection of 160 000 compounds.
Original language | English |
---|---|
Pages (from-to) | 2177-2180 |
Number of pages | 4 |
Journal | Journal of Medicinal Chemistry |
Volume | 52 |
Issue number | 8 |
DOIs | |
Publication status | Published - 23 Apr 2009 |